This medical content was developed independently by a third party via an educational grant. This material is copyright protected and is provided here with their permission for educational and informational purposes only and is not certified for continuing education credits.
Home > Type 2 Diabetes > Pharmacotherapies > Pharmacokinetic, Pharmacodynamic (PK/PD) & Dosing Considerations for Rybelsus®
Pharmakinetic, Pharmacodynamic (PK/PD) & Dosing Considerations for RYBELSUS®
This video describes PK/PD considerations that can impact the dosing of RYBELSUS®.
Explore additional evidence-based resources on a variety of topics important to patient care.
type 2
diabetes
Other Therapy Areas
Explore resources in other therapeutic areas investigated by Novo Nordisk. All information is for educational purposes only and is not intended to promote any products.
Diabetes
Obesity
Rare Blood
Disorders
Rare Endocrine
Disorders
NASH
Search the Exchange
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products. It provides evidence-based information on a variety of topics important to patient care. All information is for educational purposes only and is not intended to promote any products.
Additional Information
Speak to a live medical representative.
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit https://www.novonordisk-us.com/contact-us.html or call 1-800-727-6500
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.
